Drugs / Transforming Growth Factor Beta 3
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07388069 | Dec 2025 → Dec 2026 expected | keratoconus | TheiaNova Ltd. | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Transforming Growth Factor Beta 3 | “TN-001, the study drug, is a topical eyedrop containing Transforming Growth Factor Beta 3 (TGFB3) and Dexamethasone Sodium Phosphate (DexSP).” NCT07388069 ↗ |
| Known as | TGFB3 | “TN-001, the study drug, is a topical eyedrop containing Transforming Growth Factor Beta 3 (TGFB3) and Dexamethasone Sodium Phosphate (DexSP).” NCT07388069 ↗ |
| Route | Topical | “TN-001, the study drug, is a topical eyedrop” NCT07388069 ↗ |